# Developing a Synthetic Adeno-Associated Virus (AAV) for Engineering Safer Gene Therapies

> **NIH NIH R01** · UNIVERSITY OF CALIFORNIA, SAN DIEGO · 2023 · $420,026

## Abstract

PROJECT SUMMARY
 Medicine is currently undergoing a revolution, where viable gene therapies are being developed for
multiple disorders, including diseases of the central nervous system (CNS). One of the obstacles that limits the
use of gene therapy is the availability of safe and effective vectors for widespread delivery of genes. Due to its
stable transgene expression, broad tropism, and modest immunogenicity, recombinant adeno-associated virus
(rAAV) is the most widely used viral vector for human gene therapy. Almost 200 rAAV therapies have been
completed or are currently in clinical trials, including two FDA-approved therapies for genetic diseases of the
CNS. However, evidence is mounting that rAAV-based gene therapies are not without toxicity or significant risk,
with several rAAV-related deaths and numerous adverse outcomes reported during the past three years alone.
In a recent trial for Sanfilippo syndrome, 1 patient died and others demonstrated concerning MRI changes at
rAAV injection sites within the brain, halting the study. Other rAAV trials have reported serious adverse effects
ranging from thrombocytopenia to acute kidney failure to cardio-pulmonary insufficiency. While some of these
adverse effects are thought to be caused by immune reactions to the AAV capsid or transgene, increasing
evidence indicates that the rAAV genome, which contains two 145-base pair DNA segments named inverted
terminal repeats (ITRs), is a major source of rAAV toxicity.
 While conducting fundamental experiments on learning and memory, we discovered that rAAV was toxic
to dividing neural progenitor cells (NPCs) and immature neurons, completely ablating adult neurogenesis in the
mouse hippocampus. Consistent with previous work, these experiments indicate that the AAV ITRs appear to
be sufficient and necessary for this toxicity. Embarking on a new research direction, we will utilize our
complimentary expertise in neuroscience, stem cell biology, and engineering to develop new methods for rAAV
production and create the first rAAVs with engineered ITRs that are safer for human gene therapy. These new
therapies will be particularly important in the treatment of neurodevelopmental and other diseases in children
who have active proliferation of stem/progenitor cells, which are exquisitely sensitive to rAAV toxicity. In the
current proposal we aim to:
Aim 1. Determine which components of the ITR DNA sequence are required for toxicity in NPCs in vivo.
Aim 2. Develop a cell-free synthetic rAAVs capable of packaging genomes with mutant ITRs.
Aim 3. Engineer an rAAV that will rescue loss of function in a murine model of Rett syndrome while
demonstrating less toxicity than conventional rAAVs.

## Key facts

- **NIH application ID:** 10629902
- **Project number:** 1R01NS131151-01
- **Recipient organization:** UNIVERSITY OF CALIFORNIA, SAN DIEGO
- **Principal Investigator:** Matthew Shtrahman
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2023
- **Award amount:** $420,026
- **Award type:** 1
- **Project period:** 2023-02-01 → 2028-01-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10629902

## Citation

> US National Institutes of Health, RePORTER application 10629902, Developing a Synthetic Adeno-Associated Virus (AAV) for Engineering Safer Gene Therapies (1R01NS131151-01). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10629902. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*